Home
Polpharma Biologics

Polpharma Biologics Market Share Analysis for July 2026

Polpharma Biologics is one of the most modern biotechnology companies with state-of-the-art facilities across Europe. Our customized CDMO services are available for both biosimilars and innovative molecules, including next-generation biologics.

Health > Biotechnology and Pharmaceuticals

Domainpolpharmabiologics.com

Year Founded1935

Employees1001 - 5000

Annual Revenue$2M - $5M

Polpharma Biologics

Polpharma Biologics (including company regionals)

polpharmabiologics.com

See more website traffic and engagement information

Polpharma Biologics Revenue up to July 2026 is 2M - 5M

revenue generated by Polpharma Biologics top domains

Polpharma Biologics top domains revenue over 3 years

Revenue for Polpharma Biologics top domains

polpharmabiologics.com2M - 5M

See more with Sales Intelligence

Total visits to Polpharma Biologics's top domains

Understand Polpharma Biologics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

polpharmabiologics.com3.4K

See more with Sales Intelligence

Avg. visit duration in Polpharma Biologics's top domains

Analyze Polpharma Biologics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

polpharmabiologics.com00:00:09

See more with Sales Intelligence

Avg. pageviews on Polpharma Biologics's top domains

See how Polpharma Biologics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

polpharmabiologics.com1.59

See more with Sales Intelligence

Polpharma Biologics top competitors by domain

Top similar sites in July 2026, ranked by their affinity

rynekzdrowia.plCompany NameRynek ZdrowiaEmployees201 - 500HQPoland, WarsawAnnual revenue< $1MTotal visits7.5MHealth > Public Health and Safety

Top technologies used by Polpharma Biologics

These are the website technologies, by industry, used by Polpharma Biologics top domains

Advertising (5)

DoubleClick

Widget (5)

Twemoji

Audio Video Media (3)

YouTube

Mobile (3)

Meta Viewport

More Technologies

12

See all

News & Signals from Polpharma Biologics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPolpharma Biologics Group was planning to identify as competitor of Takeda Pharmaceutical Co. on Jul 31st '26.Privately-held Swiss firm Polpharma Biologics says the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review regulatory filings for PB016, its proposed biosimilar to Takeda's (TYO: 4502) Entyvio (vedolizumab).

NewsPolpharma Biologics Group is planning to develop PB016.PB016 is being developed by Polpharma Biologics S.A., and Fresenius Kabi has exclusive commercialization rights globally, excluding the Middle East and North Africa, pending regulatory approval.

NewsPolpharma Biologics Group partnered with Fresenius Kabi on Aug 1st '25.Polpharma Biologics and Fresenius Kabi sign licensing agreement for proposed vedolizumab biosimilar PB016.